Selective BCL-2 Inhibitor Triggers STING-Dependent Antitumor Immunity via Inducing mtDNA Release

Investigators found that ABT-199 activated the STING pathway to enhance the immunotherapeutic effect, and provided a ready-to-use small molecule drug for STING signaling activation.